EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Nonmedical switch of anti-TNF-α biosimilars has no major clinical, pharmacokinetic and psychological impact on patients with IBD - the SAFER Study

Giuseppe Privitera, Lucia Monastero, Elena Melita, Elisa Schiavoni, Daniele Napolitano, Antonella Barini, Angela Barini, Barbara Tolusso, Lucrezia Laterza, Antonio Gasbarrini, Franco Scaldaferri, Daniela Pugliese und 2 weitere

Digestive and Liver Disease · 2025

DOI: 10.1016/j.dld.2025.01.206 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Digestive and Liver Disease, 2025. Verfasst von Giuseppe Privitera und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Adalimumab, Infliximab, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Biogen Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Data on nonmedical switching from one anti-Tumor Necrosis Factor (TNF)-α biosimilar to another in inflammatory bowel disease (IBD) are relatively sparse. We aimed to study the effects of nonmedical switch from infliximab biosimilar CT-P13 to SB2 and from adalimumab biosimilar ABP 501 to SB5. METHODS: In this observational study, consecutive IBD patients receiving nonmedical switch were prospectively followed-up for 12 months. The primary outcome was treatment persistence; other outcomes included: secondary effectiveness outcomes, safety, immunogenicity, inflammatory makers levels and psychometric assessments. RESULTS: A total of 119 and 76 patients were enrolled in the SB2 and SB5 cohorts. Persistence on treatment at 12 months was 84.0 % in the SB2 cohort and 78.9 % in the SB5 cohort. No clinically meaningful changes in other secondary effectiveness outcomes were recorded. Rates of 0.38 and 0.63 adverse events of interest per 100 patient-years were observed in the SB2 and SB5 cohorts. The pharmacokinetics and immunogenicity of either drug were unaffected by nonmedical switch; similarly, levels of inflammatory cytokines remained largely unchanged. No changes in psychometric assessments were recorded. CONCLUSION: Nonmedical switch of infliximab and adalimumab biosimilars does not significantly affect treatment effectiveness, safety and pharmacokinetics, nor does it have major psychological implications for patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsAdalimumabInfliximabInflammatory Bowel DiseasesDrug SubstitutionHumansMaleFemaleAdultMiddle AgedProspective StudiesTumor Necrosis Factor-alphaTreatment OutcomeAntibodies, Monoclonal

Stichwörter der Autor:innen

BiosimilarsEffectivenessInflammatory bowel diseaseSwitch

Substanzen

Biosimilar PharmaceuticalsAdalimumabInfliximabCT-P13Tumor Necrosis Factor-alphaAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
  • Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Roma, Italy.
  • IBD UNIT-CEMAD (Centro Malattie Apparato Digerente), Medicina Interna e Gastroenterologia, Fondazione Policlinico A. Gemelli IRCCS, Roma, Italy.
  • Istituto di Biochimica e Biochimica Clinica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Humanitas Research Hospital - IRCCS, Rozzano, Milan, Italy.
  • Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Roma, Italy; IBD UNIT-CEMAD (Centro Malattie Apparato Digerente), Medicina Interna e Gastroenterologia, Fondazione…

Förderung

  • Biogen Inc

Zitieren

APA

Privitera, G., Monastero, L., Melita, E., Schiavoni, E., Napolitano, D., Barini, A., Barini, A., Tolusso, B., Laterza, L., Gasbarrini, A., Scaldaferri, F., Pugliese, D., Armuzzi, A., & SAFER Study Group (2025). Nonmedical switch of anti-TNF-α biosimilars has no major clinical, pharmacokinetic and psychological impact on patients with IBD - the SAFER Study. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2025.01.206

Vancouver

Privitera G, Monastero L, Melita E, Schiavoni E, Napolitano D, Barini A, et al. Nonmedical switch of anti-TNF-α biosimilars has no major clinical, pharmacokinetic and psychological impact on patients with IBD - the SAFER Study. Digestive and Liver Disease. 2025. doi:10.1016/j.dld.2025.01.206

BibTeX
@article{Privitera2025,
  author = {Privitera, Giuseppe and Monastero, Lucia and Melita, Elena and Schiavoni, Elisa and Napolitano, Daniele and Barini, Antonella and Barini, Angela and Tolusso, Barbara and Laterza, Lucrezia and Gasbarrini, Antonio and Scaldaferri, Franco and Pugliese, Daniela and Armuzzi, Alessandro and SAFER Study Group, SAFER Study Group},
  title = {Nonmedical switch of anti-TNF-α biosimilars has no major clinical, pharmacokinetic and psychological impact on patients with IBD - the SAFER Study},
  journal = {Digestive and Liver Disease},
  year = {2025},
  doi = {10.1016/j.dld.2025.01.206}
}
Kostenlos starten →